Cytokine Mediators in Acute Respiratory Distress

Acute Respiratory Distress Syndrome (ARDS) arises from widespread lung inflammation leading to disruption of the alveolar–capillary barrier, accumulation of protein-rich oedema and severe hypoxaemia. Central to its pathogenesis is a dysregulated release of proinflammatory cytokines such as tumour necrosis factor alpha, interleukin-1β and interleukin-6, which amplify vascular permeability and recruit neutrophils and monocytes into the pulmonary interstitium. Chemokines guide leukocyte trafficking, while anti-inflammatory mediators including interleukin-10 and transforming growth factor beta attempt to restrain the cascade. The nuclear factor κB pathway serves as a master regulator of many cytokine genes, and additional modulators—such as lipid mediators and kinase-driven signalling pathways—fine-tune the inflammatory response. Patient-level genomic and proteomic analyses have revealed heterogeneity in cytokine signatures, spurring efforts towards personalised immunomodulation. Emerging therapies, from extracorporeal cytokine adsorption to mesenchymal stem cell administration, seek to quell the cytokine storm without impairing host defence. A comprehensive understanding of the interplay between pro- and anti-inflammatory networks is essential for the rational design of targeted interventions that reduce mortality and long-term disability in this globally significant syndrome.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Cytokine Mediators in Acute Respiratory Distress publication trend

The graph below shows the total number of articles in cytokine mediators in acute respiratory distress across all publications each year (not limited to Nature Index journals).

Technical terms

Acute Respiratory Distress Syndrome (ARDS): A severe inflammatory lung condition characterised by non-cardiogenic pulmonary oedema and refractory hypoxaemia.

Cytokine storm: An excessive and uncontrolled release of proinflammatory cytokines leading to widespread tissue damage.

Prostaglandin E2 (PGE2): A lipid mediator with immunomodulatory properties that can suppress inflammatory signalling.

Mesenchymal stem cells (MSCs): Multipotent stromal cells capable of modulating immune responses and promoting tissue repair.

Nuclear factor κB (NF-κB): A transcription factor that regulates the expression of many proinflammatory cytokines.

Neutrophil-to-lymphocyte ratio (NLR): A simple clinical marker reflecting the balance between innate and adaptive immune responses.

Importin α5: A nuclear transport protein that mediates the entry of stress-responsive transcription factors into the nucleus.

Stress-responsive transcription factors (SRTFs): Proteins such as NF-κB that drive gene expression programmes in response to inflammatory stimuli.

Interferon gamma (IFN-γ): An anti-viral and immunoregulatory cytokine that can modulate inflammatory damage in ARDS.

References

1. PGE2 Produced by Exogenous MSCs Promotes Immunoregulation in ARDS Induced by Highly Pathogenic Influenza A through Activation of the Wnt-β-Catenin Signaling Pathway. International Journal of Molecular Sciences (2023).
2. Screening study of peripheral blood biomarkers in sepsis-associated ARDS. MEDS Clinical Medicine (2023).
3. Protection from Endotoxin Shock by Selective Targeting of Proinflammatory Signaling to the Nucleus Mediated by Importin Alpha 5. ImmunoHorizons (2019).